BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kuhn N, Schmidt CQ, Schlapschy M, Skerra A. PASylated Coversin, a C5-Specific Complement Inhibitor with Extended Pharmacokinetics, Shows Enhanced Anti-Hemolytic Activity in Vitro. Bioconjug Chem 2016;27:2359-71. [PMID: 27598771 DOI: 10.1021/acs.bioconjchem.6b00369] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 5.7] [Reference Citation Analysis]
Number Citing Articles
1 Ricklin D, Mastellos DC, Reis ES, Lambris JD. The renaissance of complement therapeutics. Nat Rev Nephrol 2018;14:26-47. [PMID: 29199277 DOI: 10.1038/nrneph.2017.156] [Cited by in Crossref: 196] [Cited by in F6Publishing: 183] [Article Influence: 39.2] [Reference Citation Analysis]
2 Shamloo A, Rostami P, Mahmoudi A. PASylation Enhances the Stability, Potency, and Plasma Half-Life of Interferon α-2a: A Molecular Dynamics Simulation. Biotechnol J 2020;15:e1900385. [PMID: 32277577 DOI: 10.1002/biot.201900385] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Bonnard T, Jayapadman A, Putri JA, Cui J, Ju Y, Carmichael C, Angelovich TA, Cody SH, French S, Pascaud K, Pearce HA, Jagdale S, Caruso F, Hagemeyer CE. Low-Fouling and Biodegradable Protein-Based Particles for Thrombus Imaging. ACS Nano 2018;12:6988-96. [PMID: 29874911 DOI: 10.1021/acsnano.8b02588] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 6.5] [Reference Citation Analysis]
4 Harder MJ, Höchsmann B, Dopler A, Anliker M, Weinstock C, Skerra A, Simmet T, Schrezenmeier H, Schmidt CQ. Different Levels of Incomplete Terminal Pathway Inhibition by Eculizumab and the Clinical Response of PNH Patients. Front Immunol 2019;10:1639. [PMID: 31379839 DOI: 10.3389/fimmu.2019.01639] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
5 Harris CL, Pouw RB, Kavanagh D, Sun R, Ricklin D. Developments in anti-complement therapy; from disease to clinical trial. Mol Immunol 2018;102:89-119. [PMID: 30121124 DOI: 10.1016/j.molimm.2018.06.008] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 10.3] [Reference Citation Analysis]
6 Dopler A, Stibitzky S, Hevey R, Mannes M, Guariento M, Höchsmann B, Schrezenmeier H, Ricklin D, Schmidt CQ. Deregulation of Factor H by Factor H-Related Protein 1 Depends on Sialylation of Host Surfaces. Front Immunol 2021;12:615748. [PMID: 33732239 DOI: 10.3389/fimmu.2021.615748] [Reference Citation Analysis]
7 Aghaabdollahian S, Ahangari Cohan R, Norouzian D, Davami F, Asadi Karam MR, Torkashvand F, Vaseghi G, Moazzami R, Latif Dizaji S. Enhancing bioactivity, physicochemical, and pharmacokinetic properties of a nano-sized, anti-VEGFR2 Adnectin, through PASylation technology. Sci Rep 2019;9:2978. [PMID: 30814652 DOI: 10.1038/s41598-019-39776-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
8 Gembillo G, Siligato R, Cernaro V, Santoro D. Complement Inhibition Therapy and Dialytic Strategies in Paroxysmal Nocturnal Hemoglobinuria: The Nephrologist's Opinion. J Clin Med 2020;9:E1261. [PMID: 32357555 DOI: 10.3390/jcm9051261] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Gebauer M, Skerra A. Prospects of PASylation® for the design of protein and peptide therapeutics with extended half-life and enhanced action. Bioorganic & Medicinal Chemistry 2018;26:2882-7. [DOI: 10.1016/j.bmc.2017.09.016] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 6.8] [Reference Citation Analysis]
10 Abbina S, Parambath A. PEGylation and its alternatives. Engineering of Biomaterials for Drug Delivery Systems. Elsevier; 2018. pp. 363-76. [DOI: 10.1016/b978-0-08-101750-0.00014-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
11 Tesarova B, Dostalova S, Smidova V, Goliasova Z, Skubalova Z, Michalkova H, Hynek D, Michalek P, Polanska H, Vaculovicova M, Hacek J, Eckschlager T, Stiborova M, Pires AS, Neves AR, Abrantes AM, Rodrigues T, Matafome P, Botelho MF, Teixeira P, Mendes F, Heger Z. Surface-PASylation of ferritin to form stealth nanovehicles enhances in vivo therapeutic performance of encapsulated ellipticine. Applied Materials Today 2020;18:100501. [DOI: 10.1016/j.apmt.2019.100501] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
12 Mans BJ. Chemical Equilibrium at the Tick-Host Feeding Interface:A Critical Examination of Biological Relevance in Hematophagous Behavior. Front Physiol 2019;10:530. [PMID: 31118903 DOI: 10.3389/fphys.2019.00530] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
13 Sezin T, Murthy S, Attah C, Seutter M, Holtsche MM, Hammers CM, Schmidt E, Meshrkey F, Mousavi S, Zillikens D, Nunn MA, Sadik CD. Dual inhibition of complement factor 5 and leukotriene B4 synergistically suppresses murine pemphigoid disease. JCI Insight 2019;4:128239. [PMID: 31391346 DOI: 10.1172/jci.insight.128239] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
14 Murfin KE, Fikrig E. Tick Bioactive Molecules as Novel Therapeutics: Beyond Vaccine Targets. Front Cell Infect Microbiol 2017;7:222. [PMID: 28634573 DOI: 10.3389/fcimb.2017.00222] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
15 Varanko A, Saha S, Chilkoti A. Recent trends in protein and peptide-based biomaterials for advanced drug delivery. Adv Drug Deliv Rev 2020;156:133-87. [PMID: 32871201 DOI: 10.1016/j.addr.2020.08.008] [Cited by in Crossref: 57] [Cited by in F6Publishing: 42] [Article Influence: 28.5] [Reference Citation Analysis]
16 Mazaheri S, Talebkhan Y, Mahboudi F, Nematollahi L, Cohan RA, Mirabzadeh Ardakani E, Bayat E, Sabzalinejad M, Sardari S, Torkashvand F. Improvement of Certolizumab Fab' properties by PASylation technology. Sci Rep 2020;10:18464. [PMID: 33116155 DOI: 10.1038/s41598-020-74549-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Eskandarpour M, Chen YH, Nunn MA, Coupland SE, Weston-Davies W, Calder VL. Leukotriene B4 and Its Receptor in Experimental Autoimmune Uveitis and in Human Retinal Tissues: Clinical Severity and LTB4 Dependence of Retinal Th17 Cells. Am J Pathol 2021;191:320-34. [PMID: 33159884 DOI: 10.1016/j.ajpath.2020.10.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
18 Frye AM, Hart TM, Tufts DM, Ram S, Diuk-Wasser MA, Kraiczy P, Blom AM, Lin YP. A soft tick Ornithodoros moubata salivary protein OmCI is a potent inhibitor to prevent avian complement activation. Ticks Tick Borne Dis 2020;11:101354. [PMID: 31866440 DOI: 10.1016/j.ttbdis.2019.101354] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
19 Aounallah H, Bensaoud C, M'ghirbi Y, Faria F, Chmelar JI, Kotsyfakis M. Tick Salivary Compounds for Targeted Immunomodulatory Therapy. Front Immunol 2020;11:583845. [PMID: 33072132 DOI: 10.3389/fimmu.2020.583845] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
20 Harder MJ, Kuhn N, Schrezenmeier H, Höchsmann B, von Zabern I, Weinstock C, Simmet T, Ricklin D, Lambris JD, Skerra A, Anliker M, Schmidt CQ. Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation. Blood 2017;129:970-80. [PMID: 28028023 DOI: 10.1182/blood-2016-08-732800] [Cited by in Crossref: 70] [Cited by in F6Publishing: 64] [Article Influence: 11.7] [Reference Citation Analysis]
21 Chmelař J, Kotál J, Kovaříková A, Kotsyfakis M. The Use of Tick Salivary Proteins as Novel Therapeutics. Front Physiol 2019;10:812. [PMID: 31297067 DOI: 10.3389/fphys.2019.00812] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
22 Rondon A, Mahri S, Morales‐yanez F, Dumoulin M, Vanbever R. Protein Engineering Strategies for Improved Pharmacokinetics. Adv Funct Mater 2021;31:2101633. [DOI: 10.1002/adfm.202101633] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
23 Denisov SS, Dijkgraaf I. Immunomodulatory Proteins in Tick Saliva From a Structural Perspective. Front Cell Infect Microbiol 2021;11:769574. [PMID: 34722347 DOI: 10.3389/fcimb.2021.769574] [Reference Citation Analysis]
24 Macpherson A, Liu X, Dedi N, Kennedy J, Carrington B, Durrant O, Heywood S, van den Elsen J, Lawson ADG. The rational design of affinity-attenuated OmCI for the purification of complement C5. J Biol Chem 2018;293:14112-21. [PMID: 30030376 DOI: 10.1074/jbc.RA118.004043] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
25 Ram Kumar Pandian S, Arunachalam S, Deepak V, Kunjiappan S, Sundar K. Targeting complement cascade: an alternative strategy for COVID-19. 3 Biotech 2020;10:479. [PMID: 33088671 DOI: 10.1007/s13205-020-02464-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
26 Ort M, Dingemanse J, van den Anker J, Kaufmann P. Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway. Front Immunol 2020;11:599417. [PMID: 33362783 DOI: 10.3389/fimmu.2020.599417] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Michels MAHM, van de Kar NCAJ, Okrój M, Blom AM, van Kraaij SAW, Volokhina EB, van den Heuvel LPWJ. Overactivity of Alternative Pathway Convertases in Patients With Complement-Mediated Renal Diseases. Front Immunol 2018;9:612. [PMID: 29670616 DOI: 10.3389/fimmu.2018.00612] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
28 Merrill SA, Brodsky RA. Complement-driven anemia: more than just paroxysmal nocturnal hemoglobinuria. Hematology Am Soc Hematol Educ Program 2018;2018:371-6. [PMID: 30504334 DOI: 10.1182/asheducation-2018.1.371] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
29 Binder U, Skerra A. PASylation®: A versatile technology to extend drug delivery. Current Opinion in Colloid & Interface Science 2017;31:10-7. [DOI: 10.1016/j.cocis.2017.06.004] [Cited by in Crossref: 35] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
30 Khodabakhsh F, Salimian M, Hedayati MH, Ahangari Cohan R, Norouzian D. Challenges and advancements in the pharmacokinetic enhancement of therapeutic proteins. Prep Biochem Biotechnol 2021;51:519-29. [PMID: 33459157 DOI: 10.1080/10826068.2020.1839907] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Powers NE, Swartzwelter B, Marchetti C, de Graaf DM, Lerchner A, Schlapschy M, Datar R, Binder U, Edwards CK 3rd, Skerra A, Dinarello CA. PASylation of IL-1 receptor antagonist (IL-1Ra) retains IL-1 blockade and extends its duration in mouse urate crystal-induced peritonitis. J Biol Chem 2020;295:868-82. [PMID: 31819009 DOI: 10.1074/jbc.RA119.010340] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
32 Gulati NM, Stewart PL, Steinmetz NF. Bioinspired Shielding Strategies for Nanoparticle Drug Delivery Applications. Mol Pharm 2018;15:2900-9. [PMID: 29733602 DOI: 10.1021/acs.molpharmaceut.8b00292] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 10.5] [Reference Citation Analysis]
33 Breibeck J, Skerra A. The polypeptide biophysics of proline/alanine-rich sequences (PAS): Recombinant biopolymers with PEG-like properties. Biopolymers 2018;109. [PMID: 29076532 DOI: 10.1002/bip.23069] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 4.6] [Reference Citation Analysis]
34 Powers NE, Swartzwelter B, Marchetti C, de Graaf DM, Lerchner A, Schlapschy M, Datar R, Binder U, Edwards CK, Skerra A, Dinarello CA. PASylation of IL-1 receptor antagonist (IL-1Ra) retains IL-1 blockade and extends its duration in mouse urate crystal-induced peritonitis. Journal of Biological Chemistry 2020;295:868-82. [DOI: 10.1016/s0021-9258(17)49941-8] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
35 Cao S, Lv Z, Guo S, Jiang G, Liu H. An update - Prolonging the action of protein and peptide drugs. Journal of Drug Delivery Science and Technology 2021;61:102124. [DOI: 10.1016/j.jddst.2020.102124] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
36 Štibrániová I, Bartíková P, Holíková V, Kazimírová M. Deciphering Biological Processes at the Tick-Host Interface Opens New Strategies for Treatment of Human Diseases. Front Physiol 2019;10:830. [PMID: 31333488 DOI: 10.3389/fphys.2019.00830] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]